Analysts See $-0.34 EPS for Catabasis Pharmaceuticals, Inc. (CATB); SHENZHOU INTERNATION (SZHIF) Shorts Up By 24.69%

February 15, 2018 - By Hazel Jackson

Analysts expect Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) to report $-0.34 EPS on March, 15.They anticipate $0.13 EPS change or 27.66% from last quarter’s $-0.47 EPS. After having $-0.31 EPS previously, Catabasis Pharmaceuticals, Inc.’s analysts see 9.68% EPS growth. The stock decreased 10.90% or $0.17 during the last trading session, reaching $1.39. About 3.15 million shares traded or 355.01% up from the average. Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) has declined 73.74% since February 15, 2017 and is downtrending. It has underperformed by 90.44% the S&P500.

SHENZHOU INTERNATION (OTCMKTS:SZHIF) had an increase of 24.69% in short interest. SZHIF’s SI was 202,000 shares in February as released by FINRA. Its up 24.69% from 162,000 shares previously. It closed at $10.25 lastly. It is down 0.00% since February 15, 2017 and is . It has underperformed by 16.70% the S&P500.

Among 5 analysts covering Catabasis Pharmaceuticals (NASDAQ:CATB), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Catabasis Pharmaceuticals had 14 analyst reports since August 17, 2015 according to SRatingsIntel. The stock of Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) earned “Buy” rating by Citigroup on Thursday, June 9. As per Monday, August 17, the company rating was maintained by Wedbush. The stock of Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) earned “Buy” rating by Oppenheimer on Monday, August 14. The firm has “Buy” rating given on Thursday, December 22 by H.C. Wainwright. The stock of Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) has “Outperform” rating given on Wednesday, June 8 by Wedbush. The rating was upgraded by Citigroup to “Buy” on Monday, November 20. Wedbush maintained Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) on Monday, August 14 with “Buy” rating. On Tuesday, March 22 the stock rating was maintained by Citigroup with “Buy”. The firm has “Neutral” rating by Citigroup given on Thursday, October 5. The stock has “Hold” rating by Cowen & Co on Thursday, August 10.

Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products based on safely metabolized and rationally targeted linker drug discovery platform in the United States. The company has market cap of $32.09 million. The firm offers Edasalonexent, an investigational oral small molecule, which is in Phase I/II clinical trial for the treatment of duchenne muscular dystrophy (DMD). It currently has negative earnings. It is also involved in developing SMART linker conjugates that are in preclinical stage of development, including CAT-5571 for cystic fibrosis (CF) trafficking and function of CF transmembrane conductance regulator, as well as for the clearance of Pseudomonas aeruginosa; and CAT-4001 for the treatment of severe and rare neurodegenerative diseases, such as Friedreich's ataxia and amyotrophic lateral sclerosis.

Shenzhou International Group Holdings Limited, an investment holding company, engages in manufacturing, processing, and selling knitwear products. The company has market cap of $14.16 billion. It focuses on producing sportswear, casual wear, and lingerie wear. It has a 28.71 P/E ratio. It is also involved in the import and export of commodities; clothing detection; print and sale of knitwear products; retail business; and property management and leasing activities.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Hazel Jackson

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: